Transforming Growth Factor Beta-1 in Human Colorectal Cancer Patients
More details
Hide details
Yuzuncu Yıl University Medical Faculty, Van, Turkey
İstanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
Okmeydanı Training Hospital, Department of Endocrinology, Istanbul, Turkey
Haseki Training Hospital, II. General Surgery, Istanbul, Turkey
Publication date: 2011-01-11
Corresponding author
Özgür Kemik   

Department of General Surgery, Yuzuncu Yıl University Medical faculty, Van, Turkey
Eur J Gen Med 2011;8(1):53-56
Aim: Colorectal cancer patients are treated with surgery and sometimes radiotherapy and chemotherapy. Transforming growth factor beta-1 (TGF-β1) acts both as an inhibitor of tumor growth and as a promoter of tumor progression. The aim of this study was to determine the levels of TGF-β1 in plasma in colorectal cancer patients and relate these to the effect of clinicopathological variables. Method: One hundred patients scheduled for colorectal cancer surgery were included. Blood samples were taken during surgery and later assayed with enzyme linked immunsorbent assay for total TGF-β1 and active TGF-β1. Result: Total and active TGF-β1 was higher in tumor samples compared to controls (p<0.001).Total TGF-β1 was higher in patients with metastases compared to patients without. Active TGF-β1 levels were not found statistically different in patients with metastases.. Conclusion: Higher levels of total TGF-β1 in plasma at surgery may be indicate of distant metastases, Measurement of total TGF-β1 in colorectal cancer patients may be of clinical use in the future.
Journals System - logo
Scroll to top